Published :
Tables : 46
Figures : 46
Category : Healthcare
No. of Pages : 205
Report Code : HC-U4017
Rare Disease Genetic Testing Market is poised to value USD 1954.24 million by 2028 end at a CAGR of 13.9% during the forecast period 2022 to 2028. FutureWise Market Research has instantiated a report that provides an intricate analysis of Rare Disease Genetic Testing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Rare Disease Genetic Testing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Rare Disease Genetic Testing Market: • Quest Diagnostics Inc. • Centogene N.V. • Invitae Corporation • 3billion, Inc. • Arup Laboratories • Eurofins Scientific • Strand Life Sciences • Ambry Genetics • Perkin Elmer, Inc. • Macrogen, Inc. • Baylor Genetics • Color Genomics, Inc. • Health Network Laboratories • Preventiongenetics • Progenity, Inc. • Coopersurgical, Inc. • Fulgent Genetics Inc. • Myriad Genetics, Inc. • Laboratory Corporation Of America Holdings • Opko Health, Inc. (Note: The list of the major players will be updated with the latest market scenario and trends) Rare Disease Genetic Testing Market Segmentation: By Disease Type • Neurological Disorders • Immunological Disorders • Hematology Diseases • Endocrine & Metabolism Diseases • Cancer • Musculoskeletal Disorders • Cardiovascular Disorders (CVDs) • Dermatology Disease • Others By Technology • Next-Generation Sequencing (NGS) o Whole Exome Sequencing (WES) o Whole Genome Sequencing (WGS) • Array Technology • PCR-based Testing • FISH • Sanger Sequencing • Karyotyping By Specialty • Molecular Genetic Tests • Chromosomal Genetic Tests • Biochemical Genetic Tests By End User • Research Laboratories & CROs • Diagnostic Laboratories • Hospitals & Clinics By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Rare Disease Genetic Testing Market By Disease Type, By Technology, By Specialty, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Disease Type launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Rare Disease Genetic Testing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Rare Disease Genetic Testing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Rare Disease Genetic Testing Market: • Quest Diagnostics Inc. • Centogene N.V. • Invitae Corporation • 3billion, Inc. • Arup Laboratories • Eurofins Scientific • Strand Life Sciences • Ambry Genetics • Perkin Elmer, Inc. • Macrogen, Inc. • Baylor Genetics • Color Genomics, Inc. • Health Network Laboratories • Preventiongenetics • Progenity, Inc. • Coopersurgical, Inc. • Fulgent Genetics Inc. • Myriad Genetics, Inc. • Laboratory Corporation Of America Holdings • Opko Health, Inc. (Note: The list of the major players will be updated with the latest market scenario and trends) Rare Disease Genetic Testing Market Segmentation: By Disease Type • Neurological Disorders • Immunological Disorders • Hematology Diseases • Endocrine & Metabolism Diseases • Cancer • Musculoskeletal Disorders • Cardiovascular Disorders (CVDs) • Dermatology Disease • Others By Technology • Next-Generation Sequencing (NGS) o Whole Exome Sequencing (WES) o Whole Genome Sequencing (WGS) • Array Technology • PCR-based Testing • FISH • Sanger Sequencing • Karyotyping By Specialty • Molecular Genetic Tests • Chromosomal Genetic Tests • Biochemical Genetic Tests By End User • Research Laboratories & CROs • Diagnostic Laboratories • Hospitals & Clinics By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Rare Disease Genetic Testing Market By Disease Type, By Technology, By Specialty, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Disease Type launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Rare Disease Genetic Testing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Rare Disease Genetic Testing Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Rare Disease Genetic Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Rare Disease Genetic Testing Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Neurological Disorders 7.2. Immunological Disorders 7.3. Hematology Diseases 7.4. Endocrine & Metabolism Diseases 7.5. Cancer 7.6. Musculoskeletal Disorders 7.7. Cardiovascular Disorders (CVDs) 7.8. Dermatology Disease 7.9. Others 8. Rare Disease Genetic Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Next-Generation Sequencing (NGS) 8.1.1. Whole Exome Sequencing (WES) 8.1.2. Whole Genome Sequencing (WGS) 8.2.Array Technology 8.3.PCR-based Testing 8.4.FISH 8.5.Sanger Sequencing 8.6.Karyotyping 9. Rare Disease Genetic Testing Market, By Specialty Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Molecular Genetic Tests 9.2. Chromosomal Genetic Tests 9.3. Biochemical Genetic Tests 10. Rare Disease Genetic Testing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Research Laboratories & CROs 10.2. Diagnostic Laboratories 10.3. Hospitals & Clinics 11. North America Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Quest Diagnostics Inc. 17.1.1. Company Overview 17.1.2. Disease Type Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Centogene N.V. 17.2.1. Company Overview 17.2.2. Disease Type Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Invitae Corporation 17.3.1. Company Overview 17.3.2. Disease Type Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. 3billion, Inc. 17.4.1. Company Overview 17.4.2. Disease Type Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Arup Laboratories 17.5.1. Company Overview 17.5.2. Disease Type Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Eurofins Scientific 17.6.1. Company Overview 17.6.2. Disease Type Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Strand Life Sciences 17.7.1. Company Overview 17.7.2. Disease Type Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Ambry Genetics 17.8.1. Company Overview 17.8.2. Disease Type Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Perkin Elmer, Inc. 17.9.1. Company Overview 17.9.2. Disease Type Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Macrogen, Inc. 17.10.1. Company Overview 17.10.2. Disease Type Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Baylor Genetics 17.11.1. Company Overview 17.11.2. Disease Type Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Color Genomics, Inc. 17.12.1. Company Overview 17.12.2. Disease Type Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Health Network Laboratories 17.13.1. Company Overview 17.13.2. Disease Type Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Preventiongenetics 17.14.1. Company Overview 17.14.2. Disease Type Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Progenity, Inc. 17.15.1. Company Overview 17.15.2. Disease Type Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Coopersurgical, Inc. 17.16.1. Company Overview 17.16.2. Disease Type Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 17.17.Fulgent Genetics Inc. 17.17.1. Company Overview 17.17.2. Disease Type Portfolio 17.17.3. SWOT Analysis 17.17.4. Financial Overview 17.17.5. Strategic Overview 17.18.Myriad Genetics, Inc. 17.18.1. Company Overview 17.18.2. Disease Type Portfolio 17.18.3. SWOT Analysis 17.18.4. Financial Overview 17.18.5. Strategic Overview 17.19.Laboratory Corporation Of America Holdings 17.19.1. Company Overview 17.19.2. Disease Type Portfolio 17.19.3. SWOT Analysis 17.19.4. Financial Overview 17.19.5. Strategic Overview 17.20.Opko Health, Inc. 17.20.1. Company Overview 17.20.2. Disease Type Portfolio 17.20.3. SWOT Analysis 17.20.4. Financial Overview 17.20.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Rare Disease Genetic Testing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Rare Disease Genetic Testing Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Rare Disease Genetic Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Rare Disease Genetic Testing Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Neurological Disorders 7.2. Immunological Disorders 7.3. Hematology Diseases 7.4. Endocrine & Metabolism Diseases 7.5. Cancer 7.6. Musculoskeletal Disorders 7.7. Cardiovascular Disorders (CVDs) 7.8. Dermatology Disease 7.9. Others
8. Rare Disease Genetic Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Next-Generation Sequencing (NGS) 8.1.1. Whole Exome Sequencing (WES) 8.1.2. Whole Genome Sequencing (WGS) 8.2.Array Technology 8.3.PCR-based Testing 8.4.FISH 8.5.Sanger Sequencing 8.6.Karyotyping
9. Rare Disease Genetic Testing Market, By Specialty Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Molecular Genetic Tests 9.2. Chromosomal Genetic Tests 9.3. Biochemical Genetic Tests
10. Rare Disease Genetic Testing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Research Laboratories & CROs 10.2. Diagnostic Laboratories 10.3. Hospitals & Clinics
11. North America Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Quest Diagnostics Inc. 17.1.1. Company Overview 17.1.2. Disease Type Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Centogene N.V. 17.2.1. Company Overview 17.2.2. Disease Type Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Invitae Corporation 17.3.1. Company Overview 17.3.2. Disease Type Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. 3billion, Inc. 17.4.1. Company Overview 17.4.2. Disease Type Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Arup Laboratories 17.5.1. Company Overview 17.5.2. Disease Type Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Eurofins Scientific 17.6.1. Company Overview 17.6.2. Disease Type Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Strand Life Sciences 17.7.1. Company Overview 17.7.2. Disease Type Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Ambry Genetics 17.8.1. Company Overview 17.8.2. Disease Type Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Perkin Elmer, Inc. 17.9.1. Company Overview 17.9.2. Disease Type Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Macrogen, Inc. 17.10.1. Company Overview 17.10.2. Disease Type Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Baylor Genetics 17.11.1. Company Overview 17.11.2. Disease Type Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Color Genomics, Inc. 17.12.1. Company Overview 17.12.2. Disease Type Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Health Network Laboratories 17.13.1. Company Overview 17.13.2. Disease Type Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Preventiongenetics 17.14.1. Company Overview 17.14.2. Disease Type Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Progenity, Inc. 17.15.1. Company Overview 17.15.2. Disease Type Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Coopersurgical, Inc. 17.16.1. Company Overview 17.16.2. Disease Type Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 17.17.Fulgent Genetics Inc. 17.17.1. Company Overview 17.17.2. Disease Type Portfolio 17.17.3. SWOT Analysis 17.17.4. Financial Overview 17.17.5. Strategic Overview 17.18.Myriad Genetics, Inc. 17.18.1. Company Overview 17.18.2. Disease Type Portfolio 17.18.3. SWOT Analysis 17.18.4. Financial Overview 17.18.5. Strategic Overview 17.19.Laboratory Corporation Of America Holdings 17.19.1. Company Overview 17.19.2. Disease Type Portfolio 17.19.3. SWOT Analysis 17.19.4. Financial Overview 17.19.5. Strategic Overview 17.20.Opko Health, Inc. 17.20.1. Company Overview 17.20.2. Disease Type Portfolio 17.20.3. SWOT Analysis 17.20.4. Financial Overview 17.20.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics